Raymond J. Guidotti
Direttore operativo presso ApiJect Systems Corp.
Profilo
Raymond J.
Guidotti is currently the Chief Operating Officer at ApiJect Systems Corp.
Posizioni attive di Raymond J. Guidotti
Società | Posizione | Inizio |
---|---|---|
ApiJect Systems Corp.
ApiJect Systems Corp. Information Technology ServicesTechnology Services ApiJect Systems Corp. is a medical technology company that specializes in manufacturing and delivering injectable medicines and vaccines. ApiJect is based in Stamford, CT, and has subsidiaries in the United States. The private company's technology platform uses a blow-fill-seal (BFS) fill-finish process to create scalable drug delivery devices that can be produced in clinical or commercial scale. ApiJect's first device, the single-dose ApiJect prefilled injector, is a simple and scalable prefilled syringe that is being tested and reviewed for COVID-19 vaccines. The company has been awarded a $138 million contract from the U.S. Department of Defense to create a high-volume domestic capacity to supply prefilled injectors. Additionally, ApiJect has been approved for a $590 million loan to construct a multi-facility campus in Research Triangle Park, NC, which will be home to the ApiJect gigafactory, one of the world's largest pharmaceutical fill-finish facilities. The company is dedicated to making injectable medicines safe and available for everyone. The company was founded in 2015 by Marc Koska. | Direttore operativo | 01/03/2021 |
Esperienze
Posizioni ricoperte
Attive
Inattive
Società quotate in Borsa
Aziende private
Relazioni
Relazioni di 1° grado
Aziende connesse in 1º grado
Uomo
Donna
Amministratori
Dirigenti
Società collegate
Aziende private | 1 |
---|---|
ApiJect Systems Corp.
ApiJect Systems Corp. Information Technology ServicesTechnology Services ApiJect Systems Corp. is a medical technology company that specializes in manufacturing and delivering injectable medicines and vaccines. ApiJect is based in Stamford, CT, and has subsidiaries in the United States. The private company's technology platform uses a blow-fill-seal (BFS) fill-finish process to create scalable drug delivery devices that can be produced in clinical or commercial scale. ApiJect's first device, the single-dose ApiJect prefilled injector, is a simple and scalable prefilled syringe that is being tested and reviewed for COVID-19 vaccines. The company has been awarded a $138 million contract from the U.S. Department of Defense to create a high-volume domestic capacity to supply prefilled injectors. Additionally, ApiJect has been approved for a $590 million loan to construct a multi-facility campus in Research Triangle Park, NC, which will be home to the ApiJect gigafactory, one of the world's largest pharmaceutical fill-finish facilities. The company is dedicated to making injectable medicines safe and available for everyone. The company was founded in 2015 by Marc Koska. | Technology Services |
- Borsa valori
- Insiders
- Raymond J. Guidotti